We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
4d Pharma Plc | LSE:DDDD | London | Ordinary Share | GB00BJL5BR07 | ORD 0.25P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 16.36 | - | 0.00 | 01:00:00 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
0 | 0 | N/A | 0 |
Date | Subject | Author | Discuss |
---|---|---|---|
16/2/2023 13:20 | Still can’t give it a rest? 🤣 | marcus80 | |
16/2/2023 11:13 | I've accepted loseing the lot .....But until I've seen Duncan face to face on site at the ongoing business as usual DDDD pharmaceutical premises in leeds. And had questions answered .... Then NO !!! | amaretto1 | |
16/2/2023 11:07 | Let it go son.Case closed.Move on... | bluebear1 | |
16/2/2023 10:14 | Now ask yourselves.... What are AIM governance doing ? FCA ? I'd go as far to say this is corporate fraud ......Next steps ...... pointless!!!AIM should be shut down ..... | amaretto1 | |
16/2/2023 10:12 | A American hedge fund takes on the debt DDDD liabilities of another American hedge fund ....So they have now put themselves in the position of secured creditor .. first in line to DDDD assets. Administrators imo are also in the mix. Very quick to delist the company. Now what about the possible milestone payments from Merck ? Private investors have been Conned !! | amaretto1 | |
16/2/2023 10:06 | Swallow..... yes we have all lost the lot ... but it wasn't thru investors making mistakes... we were all lied to ..Cash runway etc etc ....SO selling down in tandem with a loan shark getting on board ...Then the latest scam ... Arm never had any intention of concluding this deal ... they took them to the wire..All about making it look legitimate !! | amaretto1 | |
16/2/2023 09:57 | Goodbye all, a few thousand down the drain, DP and all are and have been a disgrace. | royalalbert | |
16/2/2023 09:29 | It would appear the cards are stacked against them, maybe it isn't to good to be true ? maybe it is to good to be allowed on the market ? conventional medicine appears to be more about dependency drugs rather than curing, hence the lack of interest in developing new antibiotics. | swallowsflysouth | |
16/2/2023 08:33 | All a rouse, they had no intention of relisting. Another AIM con. | katsy | |
16/2/2023 08:01 | Thiopia, the administrators are in control, so it is they who wasted money and issued that RNS. I'm not sure their conduct has been without fault. Why did it take them a fortnight to cough up that Armistice has pulled the plug? | podium | |
15/2/2023 23:41 | Fully funded to the end of 2022. Really Duncan? Lawsuits await. | the donald | |
15/2/2023 23:39 | Because maybe he still had a glimmer of hope but that was all extinguished with his egotistical CEO. | the donald | |
15/2/2023 23:32 | If Armistice informed the Administrators on 31st January why did Alex/4D issue this RNS on 2nd February ? "Despite recent setbacks in the microbiome field experienced by other companies and the limitations on patient recruitment as a result of the administration, we are delighted that patients continue to benefit from the trial treatment. We continue to build on the body of evidence for the future development of MRx0518 and 4D's approach to Live Biotherapeutics" commented Dr. Alex Stevenson, Chief Scientific Officer, 4D pharma. "Together with the clinical, safety and biomarker data we have generated in the wider MRx018 programme, it is clear that there is an opportunity to take MRx0518 into earlier lines of treatment to improve outcomes with immunotherapy. While the safety and tolerability of MRx0518 lends itself to multiple combinations and indications, the data we have generated in RCC suggests that this provides our most viable route to market." 4D pharma is in discussion regarding next steps for this study and future pivotal studies with partners and Key Opinion Leaders. On 24 June 2022, David Pike and James Clark of Interpath Advisory were appointed as administrators of 4D Pharma plc. The administrators make no statement or representation in respect of the announcement. | thiopia | |
15/2/2023 19:18 | bye bye amaretto ! CASE CLOSED ! | marcus80 | |
15/2/2023 19:07 | Duncan missing ? | arab3 | |
15/2/2023 19:01 | And Marcus... don't think your hidden behind that key board !!! Someone else thought that ... not seen him for a while !! | amaretto1 | |
15/2/2023 18:53 | how much you lost on that gamble amaretto?? you ignored the warnings .. you can only blame but yourself! how many here told you that It was a big RED FLAG ?? look in the mirror and move on ;) case CLOSED | marcus80 | |
15/2/2023 16:56 | Amateurettooo … stop it please! We all faced you reality 1 year ago!! You lost! Game over ! Give it a rest!!! | marcus80 | |
15/2/2023 16:56 | i think you should arrange another meeting with Duncan , i will hold your jacket | arab3 | |
15/2/2023 16:42 | Merck have 5 percent of the company ......Why have they not stepped in ??Are they involved ?It truly stinks on every level | amaretto1 | |
15/2/2023 15:54 | Armistice had NO intention of concluding this deal.They just basically bought DDDD for the debt of OF .....A complete set up ...I've a considerable amount of family in New York !! | amaretto1 |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions